The Zenflow Spring System EU Safety and Performance Study
NCT ID: NCT03577236
Last Updated: 2021-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2019-01-16
2024-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Zenflow Spring System Safety, Performance and Effectiveness Study
NCT03595735
The Zenflow Spring System Feasibility and Safety Study
NCT02786290
The Zenflow Spring System Safety and Performance Study (ZEST CAN)
NCT04309695
Safety and Effectiveness Study of the Zenflow Spring System
NCT04987138
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
NCT02961114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zenflow Spring System
Receives treatment with the investigational device
Zenflow Spring System
The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zenflow Spring System
The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient or patient's legal representative has been informed of the nature of the study, agrees to participate and has signed the informed consent form
3. ≥ 45 years of age
4. Baseline IPSS score \> 13, and a baseline Quality of Life (QoL) question score \> 3
5. Prostate volume 25 - 80 cc by Trans Rectal Ultrasound (TRUS) or abdominal ultrasound, measured within past 90 days and prostatic urethral length between 2.5- 4.5 cm
6. Failed, intolerant, or patient choice to not take a medication regimen for the treatment of LUTS
7. Patient must meet ONE of the following criteria:
1. Baseline PSA \<= 2.5ng/mL
2. Baseline PSA \>2.5 ng/mL and \<=10 ng/mL AND free PSA \>=25% of total PSA (no biopsy required or negative biopsy)
3. Baseline PSA \>10ng/mL AND negative prostate biopsy1 result within 12 months
4. Negative prostate biopsy1 within 12 months if abnormal digital rectal examination
5. 3 Tesla MRI of the prostate, with normal findings, within 12 months prior to the baseline visit
Exclusion Criteria
2. Urethral stricture, meatal stenosis, or bladder neck obstruction - either current, or recurrent requiring 2 or more dilations as reported in the patient's history
3. Requiring self-catheterization to void
4. Baseline PSA \> 10 ng/mL or confirmed or suspected prostate cancer
5. Any of the following, taken from a single uroflowmetry reading:
1. Peak urinary flow rate \> 12 ml/second
2. Post-void residual (PVR) \> 250 ml
3. Peak Urinary flow rate of \> 15 ml/second
4. \< 125ml urinary volume voided at baseline (pre-bladder urinary volume of ≥ 150 ml required)
6. Other condition or disease that might cause urinary retention
7. History of other diseases causing voiding dysfunction
8. Concomitant Urinary Tract Infection (UTI) (subject can be enrolled following successful treatment of UTI and a clean urine test), or a history of recurrent or chronic UTIs (defined as 2 or more UTIs in the past 12 months)
9. Concomitant bladder stones
10. Previous pelvic irradiation or radical pelvic surgery
11. Previous prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate
12. Chronic prostatitis, or recurring prostatitis within the past 12 months
13. Known allergy to nickel
14. Life expectancy less than 24 months
15. Use of concomitant medications (e.g., anticholinergics, antispasmodics or antidepressants) affecting bladder function
16. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy not prohibited)
17. Taking 5-alpha reductase inhibitors within 3 months of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study)
18. Taking one of the following within 2 weeks of pre-treatment (baseline) evaluation:
1. alpha-blockers,
2. androgens,
3. anticholinergics, or
4. cholinergic medication gonadotropin releasing hormonal analogs
19. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation:
1. phenylephrine, or
2. pseudoephedrine
20. Future fertility concerns
21. Any severe illness that might prevent study completion or would confound study results
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zenflow, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Gilling, MD
Role: PRINCIPAL_INVESTIGATOR
Tauranga Urology Research Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Australian Clinical Trials
Wahroonga, New South Wales, Australia
South Coast Urology
Wollongong, New South Wales, Australia
Goldfields Urology
Bendigo, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Urology Bay of Plenty
Tauranga, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Janelle Brennan, Miss, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLIN-0050
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.